FDA Looking Into Multaq, Actos for Potential Safety Concerns

The FDA is raising new safety concerns about several drugs including Sanofi-Aventis’ heart medication Multaq and Takeda’s blockbuster diabetes drug Actos. The drugs, both of which have already been the subject of FDA safety reviews in recent months, are now among more than a dozen products being investigated for additional concerns, the agency says in a safety update posted on its website. The preliminary reviews were started based on information the FDA received from its adverse event reporting system between July and September of last year, the agency says.
Washington Drug Letter